Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Claudia Scarsi"'
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 18, Iss 5 (2015)
Purpose: Clinical studies have suggested that proton pump inhibitors may decrease levothyroxine absorption and an in vitro study suggested that the effect of pH on dissolution may differ with formulation. To determine the impact of formulation on the
Externí odkaz:
https://doaj.org/article/8dd88cfd3a754744946607c674c6eae4
Autor:
Murray, Ducharme, Claudia, Scarsi, Elisa, Bettazzi, Giuseppe, Mautone, Yvette, Lewis, Francesco S, Celi
Publikováno v:
Thyroid. 32:897-904
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b2172fbe4491c4ea43b4d961c0c43fb
https://doi.org/10.1089/thy.2021.0604
https://doi.org/10.1089/thy.2021.0604
Autor:
Issac Sachmechi, Kenneth D Burman, Giuseppe Mautone, Gabriele Lanzi, Patricia L Moriarty, Claudia Scarsi, Leonard Wartofsky
Publikováno v:
Journal of the Endocrine Society. 6:A859-A860
Levothyroxine sodium (LT4) absorption is known to be affected by proton pump inhibitors (PPIs). Normal gastric acid secretion is important for the subsequent intestinal absorption of LT4. A reduced gastric acidity may diminish the dissolution of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0d3bdc4c7476bf349c0487924b8df49
https://doi.org/10.1210/jendso/bvac150.1777
https://doi.org/10.1210/jendso/bvac150.1777
Publikováno v:
Clinical Pharmacology in Drug Development
A new formulation of levothyroxine sodium has been developed in the form of an oral solution contained in unit‐dose ampules. A study has been conducted to compare the bioavailability of levothyroxine sodium oral solution and levothyroxine sodium so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a38ebb39b5ff021cd36a87d88e42063d
https://doi.org/10.1002/cpdd.608
https://doi.org/10.1002/cpdd.608
Publikováno v:
Endocrine Practice. 27:S185
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a27aff5018c36964eab5f5450360510
https://doi.org/10.1016/j.eprac.2021.04.861
https://doi.org/10.1016/j.eprac.2021.04.861
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 54:135-143
Objective To assess the bioequivalence (BE) potential under fasting conditions between levothyroxine soft capsules and the European reference tablet formulation. Methods Two studies were conducted to assess the BE potential as per European regulation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04181515766f956e1ba786d28143d630
https://doi.org/10.5414/cp202485
https://doi.org/10.5414/cp202485
Publikováno v:
Prostaglandins, Leukotrienes and Essential Fatty Acids. 96:11-16
The high complexity of n-3 fatty acids absorption process, along with the huge amount of endogenous fraction, makes bioavailability studies with these agents very challenging and deserving special consideration. In this paper we report the results of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d541875e0f4d1430ee52fcd3ecb2afb
https://doi.org/10.1016/j.plefa.2014.12.006
https://doi.org/10.1016/j.plefa.2014.12.006
Publikováno v:
Clinical Drug Investigation. 34:19-25
Low-dose acetylsalicylic acid (ASA; aspirin) is well-established as a platelet anti-aggregating agent for the secondary prevention of cardiovascular events. The objective of this study was to investigate the non-inferiority of a novel ASA 75 mg soft-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33ca94bc324058268660715bc0ffac7f
https://doi.org/10.1007/s40261-013-0145-2
https://doi.org/10.1007/s40261-013-0145-2
Publikováno v:
Therapeutic Drug Monitoring. 33:355-361
To assess the pharmacokinetic equivalence of a new soft capsule formulation of levothyroxine versus a marketed reference product and to assess the soft capsule formulated with stricter potency guidelines versus the capsule before the implementation o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c27fdb119c2f5f8a0e74a9501fd76252
https://doi.org/10.1097/ftd.0b013e318217b69f
https://doi.org/10.1097/ftd.0b013e318217b69f
Publikováno v:
European Journal of Clinical Pharmacology. 65:503-510
To assess the comparative pharmacokinetic profile and bioavailability of docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) after multiple-dose administration of a new oral formulation (test formulation) and a commercially available reference for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::691fd72d34729a0efb80ac32c1c4c7fd
https://doi.org/10.1007/s00228-008-0605-4
https://doi.org/10.1007/s00228-008-0605-4